Tocilizumab May Benefit Certain Severe COVID-19 Patients

(MedPage Today) -- Patients with moderate to severe cases of COVID-19-associated pneumonia and higher levels of C-reactive protein (CRP) may benefit most from tocilizumab (Actemra), a post-hoc analysis of a French study suggested.
Among patients...